Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 10/20 | 0.41 |
| ▸ | NR1H3 | Q13133 | 9/20 | 0.41 |
| ▸ | RXRA | P19793 | 7/20 | 0.41 |
| ▸ | RIPK1 | Q13546 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.38 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.38 |
| ▸ | BTK | Q06187 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29641539 | 1.00 | NR1H2 (0.41) | NR1H2NR1H3RXRARIPK1MAPT | |
| SCHEMBL29641554 | 0.92 | NR1H2 (0.42) | NR1H2NR1H3RXRARIPK1MAPT | |
| SCHEMBL22504986 | 0.92 | NR1H2 (0.42) | NR1H2NR1H3RXRARIPK1MAPT | |
| SCHEMBL22498252 | 0.88 | SCD5 (0.40) | RIPK1BTK | |
| SCHEMBL22504967 | 0.81 | PIK3CD (0.39) | — | |
| SCHEMBL29641506 | 0.81 | PIK3CD (0.39) | — | |
| SCHEMBL6960066 | 0.72 | RIPK1 (0.69) | NR1H2NR1H3RIPK1TSHRALDH1A1 | |
| SCHEMBL18642714 | 0.72 | RIPK1 (0.69) | NR1H2NR1H3RIPK1TSHRALDH1A1 | |
| SCHEMBL878861 | 0.71 | NPSR1 (0.56) | NR1H2NR1H3RIPK1MAPTNPSR1 | |
| SCHEMBL30878559 | 0.71 | RIPK1 (0.51) | NR1H2NR1H3RIPK1MAPTNPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3947384-B1 | ISOCHROMENE DERIVATIVES AS PHOSPHOINOSITIDE 3-KINASES INHIBITORS | CHIESI FARM SPA (IT) | 2023-11-01 | — | — | EP | disclosed |
| US-20220175784-A1 | ISOCHROMENE DERIVATIVES AS PHOSPHOINOSITIDE 3-KINASES INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2022-06-09 | — | — | US | disclosed |
| WO-2020200918-A1 | ISOCHROMENE DERIVATIVES AS PHOSPHOINOSITIDE 3-KINASES INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2020-10-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220175784-A1 | ISOCHROMENE DERIVATIVES AS PHOSPHOINOSITIDE 3-KINASES INHIBITORS | PIKFYVE, PDPK1, PIK3R5 | NR1H2 389/4885NR1H3 346/4885RXRA 4037/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.